Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

Stopped Study was terminated early for business purposes and as a result of a strategic decision to shift focus to another indication.

Conditions

• Type 2 Diabetes Mellitus
• Diabetic Nephropathy
• Diabetic Kidney Disease

Interventions

• DRUG: FG-3019
• DRUG: FG-3019
• DRUG: Placebo

Sponsor

Kyntra Bio